Results 181 to 190 of about 19,015 (246)

Burden of long‐term conditions and management of people with overweight and obesity: Data from the United Kingdom primary care cohort of the IMPACT‐O study

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1683-1692, March 2026.
Abstract Aims The multi‐country epIdeMiology landscape PAtient Care paThways of Obesity (IMPACT‐O) retrospective cohort study utilised existing electronic medical records to gather data on overweight and obesity. We report UK data on obesity‐related complications (ORCs) and management strategies.
Kamlesh Khunti, Matt Capehorn, Esther Artime, Lill‐Brith von Arx, Alun L. Davies, Atif Adam, Anastasia Lampropoulou   +6 more
wiley   +1 more source

GLP-1 agonist, semaglutide use in acute pulmonary embolism recovery: a four-week proof-of-concept study including proteomic profiling. [PDF]

Eur Heart J Open
Samaranayake CB, Chen YC, Fang M, Rhodes CJ, Song S, Sabrin F, Ashek A, Bonnici K, Mukherjee B, Howard LS, Pinguel J, Rawal B, Semple T, Price LC, Wort SJ, Rudd T, Zhao L, McCabe C.   +17 more
europepmc   +1 more source

Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia. [PDF]

Patient Prefer Adherence
Ali MAS, Amirthalingam P, Alshareef H, Alqifari SF, Elsaid Hamdan AM, Alatawi O, Hakami FAM, Albalawi NS, Aljabri A.   +8 more
europepmc   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1956-1971, March 2026.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore)
Dutta D, Kamrul-Hasan ABM, Jindal R, Mohindra R, Nagendra L, Bhattacharya S.   +5 more
europepmc   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 1984-1996, March 2026.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Abusedera O, Sherif J, Smida M, Fredericks S.   +3 more
europepmc   +1 more source

Mental health changes after 4 months of weight loss treatment with the glucagon‐like peptide‐1 analogue liraglutide 3.0 mg

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2095-2104, March 2026.
Abstract Objective This observational study examined changes in mental health and wellbeing after 4‐months liraglutide 3.0 mg treatment in patients with obesity and explored associations with weight loss. Methods We included 98 patients with obesity treated with liraglutide 3.0 mg.
Susanne Kuckuck, Nina van Gerwen, Johanneke E. Oosterman, Mesut Savas, Maryam Kavousi, Brenda W. J. H. Penninx, Mariëtte R. Boon, Elisabeth F.C. van Rossum   +7 more
wiley   +1 more source

Semaglutide versus caloric restriction‐induced weight loss: insights into effects on skeletal muscle mass and function

The Journal of Physiology, EarlyView.
Harsh Shah, Julio E. Ayala
wiley   +1 more source

The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

JACC Adv
Kumar S, Anderson JE, Coviello A, Lopez-Jimenez F, Bakris GL.   +4 more
europepmc   +1 more source